Source: Breathe, 16 (1) 190321; 10.1183/20734735.0321-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Guillermo Suarez-Cuartin, Maria Molina-Molina. Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients. Breathe, 16 (1) 190321; 10.1183/20734735.0321-2019

Member's Comments

No comment yet.

Related content which might interest you: The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012 Autoantibodies in patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Prognostic evaluation in Chinese patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Clinical features and predictive factors for acute exacerbation of idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical aspects of idiopathic pulmonary fibrosis Year: 2007 Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Clinical features of patients with idiopathic pulmonary upper lobe-dominant fibrosis Source: International Congress 2016 – Orphan diseases I Year: 2016 Familial cases of idiopathic pulmonary fibrosis: Clinical observation Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis Year: 2011 Prognostic evaluation in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Towards a better diagnosis of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 108-113 Year: 2011 Clinical and radiological variants of fibrosis pulmonary sarcoidosis Source: Virtual Congress 2020 – Clinical issues in granulomatous lung diseases Year: 2020 Differences between ANCA positive and negative lung fibrosis cases without vasculitis Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 Comparison of clinical characteristics and prognosis in patients with idiopathic pulmonary upper lobe predominant pulmonary fibrosis and idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Clinical and pathological findings of patients with interstitial lung diseases associated with antisynthetase other than Jo-1 antibodies Source: Eur Respir J 2005; 26: Suppl. 49, 541s Year: 2005 Prognosis of pulmonary fibrosis with usual interstitial pneumonia pattern in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-related nephritiss Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020